49 results on '"Ratziu, Vlad"'
Search Results
2. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol
3. Clinical Trial Landscape in NASH
4. Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
5. Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study
6. The necroptosis-inducing pseudokinase mixed lineage kinase domain-like regulates the adipogenic differentiation of pre-adipocytes
7. Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
8. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
9. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B
10. Real-World Burden of Nonalcoholic Steatohepatitis
11. Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes
12. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
13. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
14. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
15. Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants
16. Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases
17. Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
18. Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis
19. The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis B and Drug-Induced Liver Disease
20. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis
21. Liver Biopsy Analysis Has a Low Level of Performance for Diagnosis of Intermediate Stages of Fibrosis
22. 521 ALT, FIBROSCAN VCTE, AND FIBROSCAN CAP AS PREDICTIVE MARKERS OF RESMETIROM BIOPSY RESPONSE
23. FINAL RESULTS FROM THE PHASE 3 REGENERATE TRIAL EVALUATING THE EFFECTS OF OBETICHOLIC ACID IN PATIENTS WITH PRE-CIRRHOTIC FIBROSIS DUE TO NONALCOHOLIC STEATOHEPATITIS
24. SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
25. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI)
26. A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C
27. Pharmacologic Therapy of Non-Alcoholic Steatohepatitis
28. Screening for Liver Fibrosis by Using a Noninvasive Biomarker in Patients With Diabetes
29. 451 NEW SAFETY AND EFFICACY ANALYSES FROM THE REGENERATE TRIAL OF OBETICHOLIC ACID FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS
30. Transcriptional activation of endoglin and transforming growth factor-β signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury
31. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C
32. EFFECT OF INTERFERON THERAPY ON THE NATURAL HISTORY OF HEPATITIS C VIRUS-RELATED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
33. 334 OBETICHOLIC ACID IMPROVES EXPERIMENTAL NON-INVASIVE MARKERS OF NON-ALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS; RESULTS OF A SECONDARY ANALYSIS FROM THE MONTH-18 INTERIM ANALYSIS OF THE REGENERATE STUDY
34. 326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY
35. 357 - Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2B Centaur Study
36. NAFLD Phenotype in Patients With V-ATPase Proton Pump Assembly Defects
37. 354 - Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
38. 507 APRI and FIB-4 Index Scores Can Enrich for Subjects With Fibrotic Non-Alcoholic Steatohepatitis (NASH) in Clinical Trials - The CENTAUR Trial Data
39. Reply
40. Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations
41. 1075 Diagnostic value of biochemical markers (fibrotest) for the prediction of liver fibrosis in patients with chronic alcoholic liver disease (ALD)
42. 1003 A prospective assessment of “a la carte” regimen of PEG interferon alpha 2B and ribavirin combination in patients with chronic hepatitis C (CHC)
43. 949 Low HBV replication and liver fibrosis: the impact of race in a study of 552 chronic hepatitis B patients
44. 729 Diagnostic value of biochemical markers (fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)
45. 582 A prospective follow-up of discordances between biochemical markers and biopsy in patients with chronic hepatis C (CHC)
46. 559 An overview of biochemical markers (fibrotest-actitest) diagnostic value in chronic liver diseases: A non-invasive alternative to liver biopsy
47. 549 Hepatitis C in 2,410 patients 65 years or older. A severe and neglected curable disease?
48. 284 Diagnostic value of fibrosis biochemical markers (fibrotest) for the screening of oesophageal varices in patients with chronic liver disease
49. 282 Diagnostic value of fibrosis biochemical markers (fibrotest) for the prediction of portal hypertension in chronic liver disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.